Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Camrelizumab + Apatinib in Advanced HCC
NCT05550025Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05550025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550025.